Randomized trial developed a prognostic model to predict survival in diffuse large B-cell lymphoma, suggesting improved risk stratification.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid-liquid phase separation (LLPS)-related prognostic model to improve risk stratification. Transcriptomic and clinical data from four cohorts (n = 768) were analysed. Multiple machine learning algorithms were applied to identify prognostic LLPS-related genes (LRGs) and construct a 6-LRG model. Model performance was assessed using survival analysis, time-dependent receiver operating characteristic curves and multivariable modelling. Additional analyses were conducted to explore potential biological and microenvironmental differences between risk groups. The 6-LRG model stratified patients into groups with significantly different overall survival across datasets, with 1-year area under curve (AUCs) ranging from 0.661 to 0.820, 3-year AUCs from 0.683 to 0.779 and 5-year AUCs from 0.711 to 0.807. The 6-LRG model remained independent of established clinical variables and improved risk prediction when integrated into a nomogram. Distinct biological and immune characteristics were observed between groups. The 6-LRG model may provide additional prognostic information in DLBCL and generates hypotheses regarding underlying biological mechanisms. However, prospective validation in larger populations is essential before any implementation.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: